中国介入心脏病学大会(CIT)会议纪要

由中华医学会心血管病学分会、中国介入心脏病学大会(CIT)理事会、美国心血管研究基金会(Cardiovascular ResearchFoundation)-经导管心血管治疗学大会(TCT)、欧洲经皮血管重建治疗大会(EuroPCR)联合主办、中国工程院医药卫生学部等多个单位协办的“中国介入心脏病学大会(CIT)2007暨TCT atCIT和EuroPCR at CIT”于2007年3月29～4月1日在北京国际会议中心召开。来自39个国家和地区的100余位世界知名专家应邀出席大会,近400名来自境外的医生及2500余名国内医生注册参加大会。美国TCT以及欧洲UuroPCR这两个世界最著名的心血管介…     

用参三七、杜仲和黄精组成的草药合剂阻止金属诱导的肝细胞氧化损伤或抑制肝癌发生

US2006105061-A1该草药合剂是以参三七、杜仲和黄精根茎为主要成分,能有效抑制金属(如铜、钒、铁)诱导的肝细胞氧化损害(如脂质过氧化和溶酶体变形),还可抑制肝癌的发生,提高致癌物代谢酶(谷胱甘肽过氧化物酶、谷胱甘肽还原酶、葡萄糖-6-磷酸脱氢酶、过氧化氢酶、谷胱甘肽S-转移酶或醌还原酶)的活性,致癌物代谢酶是细胞色素P450(CYP)异构相酶和相酶。该草药合剂中各成分间具有协同作用,易吸收,起效快,作用持久。用参三七、杜仲和黄精组成的草药合剂阻止金属诱导的肝细胞氧化损伤或抑制肝癌发生@高展…     

用固相微萃取和气-质联用技术分析菘蓝叶中的挥发性成分

异硫腈酸盐是芥属蔬菜中典型的成分,具有化学防癌作用。由于菘蓝Isatis tinctoria L.叶中可能存在挥发性异硫腈酸盐,且对该植物中挥发性成分的研究鲜有报道,因此作者采用顶空固相微萃取(HS-SPME)和气-质(GC-MS)联用技术分析菘蓝叶中的挥发性成分。将3.5g样品溶于含5mL水的管形瓶中,平衡30min,在750r/min条件下搅拌萃取25min,萃取温度30℃。用于分析物热解吸的固定相纤维保持在260℃,共3min,观察多项参数对萃取最佳化的影响。在GC-MS分析中,采用带有Varian2000离子阱质谱仪的Varian3800气相色谱仪。使用2种不同的溶凝硅石毛细管柱:1)…     

医源性食管穿孔15例原因及处理

医源性食管穿孔是一严重疾患，如不及时诊断和治疗，可危及病人生命，死亡率在20％以上。我院1990～2007年共收治医源性食管穿孔15例，效果满意现报道如下。     

含乌司他丁肺保护液在心肺转流术中的肺保护作用

Objective To evaluate protective effects of hypothermic pulmonary protective solution with uli-nastatin on lung function during cardiopulmouary bypass (CPB) in the patients with congenital heart disease(CHD) and pulmonary hypertenion. Method Fifty-four children,who had CHD of left-to-fight shunts with moderate-se-rious pulmonary hypertension, were enrolled. They had been performed with the radical operation under CPB from September 2005 to December 2006 in the Department of Cardiovascular Surgery, Children' s Hospital of Zhejiang University. Moderate-serious pulmonary hypertension was defined as pulmonary-to-systolic pressure ratio > 0.45(Pp/Ps > 0.45). Fifty-four children were randomly divided into three groups. Patients in group A (n = 18)didn't receive pulmonary protective solution, and scrved as control; patients in group B (n = 18) were adminis-tered with pulmonary protective solution without ulinastatin;patients in group C (n = 18) were administered with pulmonary protective solution with ulinastatin. The serum concentrations of MDA and MPO were measured at five different time points:pre-operation, 0 h, 3 h, 6 h and 24 h in the intensive care unit (ICU) (T1～5). Patients'lung functions were monitored at T1 - T4. The time of mechanical ventilation was recorded. Results No one died in this study. The mean time of mechanical ventilation was shorter in the group B and group C than that in the group A. The MDA and MPO levels were lower in group B compared with group A at T4. The MDA level at T3-T5 and the MPO level at T4 was lower in group C than those in group A. There were no significant in MDA and MPO levels between group B and group C at five time point.A-aDO2 was lower in groups B and C than those in group A at T3 and T4, whereas at T4, A-aDO2 was lower in group C than that in group B. Cdyn was higher in group B at T3and group C at T3 - T4 than those in group A. Cdyn was lower in groups C than that in group B at T4.Condusions Lung perfusion with hypothermic protective solution during CPB can all lung injury and promote recovery after operation, especialy with ulinastatin.     

含乌司他丁肺保护液在心肺转流术中的肺保护作用

Objective To evaluate protective effects of hypothermic pulmonary protective solution with uli-nastatin on lung function during cardiopulmouary bypass (CPB) in the patients with congenital heart disease(CHD) and pulmonary hypertenion. Method Fifty-four children,who had CHD of left-to-fight shunts with moderate-se-rious pulmonary hypertension, were enrolled. They had been performed with the radical operation under CPB from September 2005 to December 2006 in the Department of Cardiovascular Surgery, Children' s Hospital of Zhejiang University. Moderate-serious pulmonary hypertension was defined as pulmonary-to-systolic pressure ratio > 0.45(Pp/Ps > 0.45). Fifty-four children were randomly divided into three groups. Patients in group A (n = 18)didn't receive pulmonary protective solution, and scrved as control; patients in group B (n = 18) were adminis-tered with pulmonary protective solution without ulinastatin;patients in group C (n = 18) were administered with pulmonary protective solution with ulinastatin. The serum concentrations of MDA and MPO were measured at five different time points:pre-operation, 0 h, 3 h, 6 h and 24 h in the intensive care unit (ICU) (T1～5). Patients'lung functions were monitored at T1 - T4. The time of mechanical ventilation was recorded. Results No one died in this study. The mean time of mechanical ventilation was shorter in the group B and group C than that in the group A. The MDA and MPO levels were lower in group B compared with group A at T4. The MDA level at T3-T5 and the MPO level at T4 was lower in group C than those in group A. There were no significant in MDA and MPO levels between group B and group C at five time point.A-aDO2 was lower in groups B and C than those in group A at T3 and T4, whereas at T4, A-aDO2 was lower in group C than that in group B. Cdyn was higher in group B at T3and group C at T3 - T4 than those in group A. Cdyn was lower in groups C than that in group B at T4.Condusions Lung perfusion with hypothermic protective solution during CPB can all lung injury and promote recovery after operation, especialy with ulinastatin.     

含乌司他丁肺保护液在心肺转流术中的肺保护作用

Objective To evaluate protective effects of hypothermic pulmonary protective solution with uli-nastatin on lung function during cardiopulmouary bypass (CPB) in the patients with congenital heart disease(CHD) and pulmonary hypertenion. Method Fifty-four children,who had CHD of left-to-fight shunts with moderate-se-rious pulmonary hypertension, were enrolled. They had been performed with the radical operation under CPB from September 2005 to December 2006 in the Department of Cardiovascular Surgery, Children' s Hospital of Zhejiang University. Moderate-serious pulmonary hypertension was defined as pulmonary-to-systolic pressure ratio > 0.45(Pp/Ps > 0.45). Fifty-four children were randomly divided into three groups. Patients in group A (n = 18)didn't receive pulmonary protective solution, and scrved as control; patients in group B (n = 18) were adminis-tered with pulmonary protective solution without ulinastatin;patients in group C (n = 18) were administered with pulmonary protective solution with ulinastatin. The serum concentrations of MDA and MPO were measured at five different time points:pre-operation, 0 h, 3 h, 6 h and 24 h in the intensive care unit (ICU) (T1～5). Patients'lung functions were monitored at T1 - T4. The time of mechanical ventilation was recorded. Results No one died in this study. The mean time of mechanical ventilation was shorter in the group B and group C than that in the group A. The MDA and MPO levels were lower in group B compared with group A at T4. The MDA level at T3-T5 and the MPO level at T4 was lower in group C than those in group A. There were no significant in MDA and MPO levels between group B and group C at five time point.A-aDO2 was lower in groups B and C than those in group A at T3 and T4, whereas at T4, A-aDO2 was lower in group C than that in group B. Cdyn was higher in group B at T3and group C at T3 - T4 than those in group A. Cdyn was lower in groups C than that in group B at T4.Condusions Lung perfusion with hypothermic protective solution during CPB can all lung injury and promote recovery after operation, especialy with ulinastatin.     

瘤颈栓塞治疗颅内动脉瘤破裂的单臂研究

目的探讨动脉瘤颈部血管内弹簧圈栓塞术(ECE)治疗具有血泡形成颅内动脉瘤破裂(RICABF)的有效性和安全性。方法回顾性分析86例RICABF患者临床资料,包括继发性破裂/出血率,颈内动脉瘤栓塞率,残余/复发性动脉瘤,术中事件和栓塞后并发症,以及格拉斯哥结局量表(扩展)(GOS-E)的改善。结果动脉瘤完全闭塞72个(72/86,83.7%),颈部残留12个(12/86,14.0%),残留动脉瘤2个(2/86,2.3%)。术后GOS-E评分3分3例(3.5%),4分10例(11.6%),5分73例(84.9%)。所有患者行随访血管造影(平均9.0个月)。复发3例(3/86,3.5%)。没有报告提示动脉瘤破裂或出血。结论瘤颈部ECE是RICABF的有效且安全的治疗方式,其长期有效性和安全性需要在前瞻性和比较性研究中进行调查。     

束支传导阻滞对冠状动脉介入治疗后急性冠状动脉综合征患者长期预后影响的研究

目的:探讨束支传导阻滞(BBB)对接受经皮冠状动脉介入治疗(PCI)的急性冠状动脉综合征(ACS)患者预后的影响。方法:本研究纳入2013-01至2013-12于中国医学科学院阜外医院行PCI的ACS患者6 429例。根据出院诊断中是否包含BBB,将患者分为BBB组(n=159)和非束支传导阻滞(NBBB)组(n=6 270),分析比较两组2年主要不良心脑血管事件(MACCE,包括全因死亡、心原性死亡、心肌梗死、血运重建、支架内血栓形成、脑卒中)发生率的差异,并评估BBB与行PCI的ACS患者临床结局的相关性。结果:BBB组患者年龄较NBBB组更高[(62.97±11.37)岁vs(58.26±10.36)岁],体重指数更低[(25.31±3.02)kg/m2 vs(25.89±3.20)kg/m~2],肾小球滤过率[(86.89±16.15)ml/min vs(91.05±15.53)ml/min]和左心室射血分数[(59.27±9.86)%vs(62.37±7.36)%]更低,组间比较差异均有统计学意义(P均0.05),两组在其余基线指标以及冠状动脉造影与介入治疗上的差异均无统计学意义(P均0.05)。2年随访时,BBB组的心原性死亡(2.5%vs 0.7%)和支架内血栓形成(3.1%vs 0.8%)发生率均显著高于NBBB组(P均0.05),其余MACCE发生率无显著差异(P均0.05)。但经倾向性评分调整后,2年随访时两组的MACCE发生率差异无统计学意义(P0.05),BBB组中的左束支传导阻滞患者、右束支传导阻滞患者与NBBB患者在所有MACCE发生率上的差异也均无统计学意义(P均0.05)。Cox回归分析提示,合并BBB与PCI后ACS患者临床结局无明显关联。结论:对于行PCI的ACS患者,BBB并不是远期MACCE的独立危险因素。     

ST段抬高型心肌梗死非罪犯病变血运重建的指导策略：现状与研究进展

ST段抬高型心肌梗死（STEMI）合并多支血管病变（MVD）是冠心病的高危类型。早期开通梗死相关动脉,恢复心肌组织的血液灌注,可显著降低急性期死亡率。然而,非梗死相关动脉上存在的非罪犯病变仍存在风险,对患者远期预后具有很重要的影响。采用何种手段精准评估此类病变的临床意义和预后价值,并优化非罪犯病变的血运重建策略目前尚有争议。本文拟对STEMI合并MVD患者的非罪犯病变血运重建指导策略的研究现状及进展进行综述。